Ask AI
ProCE Banner Activity

Unlocking the Full Potential of PROTAC ER Degraders in ER+/HER2- MBC: Novel Mechanisms, Testing Applications, and Data Insights to Address Unmet Needs

Slideset

Download these slides from a live webinar on current clinical trial data and future directions for novel PROTAC ER degraders in ER+/HER2- MBC, including in patients with ESR1 mutated tumors. 

Released: October 17, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Pfizer, Inc. and Arvinas.

Arvinas

Pfizer, Inc.

Target Audience

This activity is intended for medical oncologists and other healthcare professionals caring for patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain the current unmet needs in ER+/HER2- mBC and the role of biomarker testing, including ESR1 mutations.

  • Differentiate the mechanisms of action between PROTAC ER degraders and other endocrine therapies.

  • Evaluate current and emerging clinical data supporting the use of PROTAC ER degraders in patients with endocrine-resistant ER+/HER2- mBC

  • Apply expert-guided treatment strategies for integrating PROTAC ER degraders in clinical practice post-CDK4/6i therapy